0,73 $
2,69 % gestern
Nasdaq, 30. Oktober, 21:00 Uhr
ISIN
US00972G1085
Symbol
AKTX
Berichte

Akari Therapeutics Plc Sponsored ADR Aktie News

Neutral
GlobeNewsWire
etwa 18 Stunden alt
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases
Neutral
GlobeNewsWire
9 Tage alt
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access the Akari CEO Corner here BOSTON and LONDON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload a...
Neutral
GlobeNewsWire
16 Tage alt
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company's American Depositary Shares (“ADSs”), each representing 2,000...
Neutral
GlobeNewsWire
22 Tage alt
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari's novel immuno-oncology...
Neutral
GlobeNewsWire
28 Tage alt
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40 th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD.
Neutral
GlobeNewsWire
etwa ein Monat alt
Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression
Neutral
GlobeNewsWire
etwa ein Monat alt
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company's antibody drug conjugate (ADC) platform using Akari's spliceoso...
Neutral
Seeking Alpha
etwa 2 Monate alt
Akari Therapeutics, Plc (NASDAQ:AKTX ) Discusses at Virtual Investor Closing Bell Series Call Company Participants Abizer Gaslightwala - CEO, President & Director Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen